Management of gynecological cancers in the COVID-19 era: a survey from Turkey
COVID-19
gynecologic oncology
survey
Journal
Journal of the Turkish German Gynecological Association
ISSN: 1309-0399
Titre abrégé: J Turk Ger Gynecol Assoc
Pays: Turkey
ID NLM: 101272522
Informations de publication
Date de publication:
04 12 2020
04 12 2020
Historique:
entrez:
4
12
2020
pubmed:
5
12
2020
medline:
5
12
2020
Statut:
ppublish
Résumé
This study aimed to investigate how gynecologic oncologists modified their patient management during Coronavirus disease-2019 (COVID-19) in Turkey. An online survey was sent to gynecologic oncology specialists and fellows in Turkey. It included management questions about strategies for newly diagnosed or recurrent endometrial, cervical, ovarian and vulvar cancer during the pandemic. Participants were asked if treatment of these cancers can be delayed or not and, if yes, the duration of delay. 32.9% of surgeons prescribed oral or intrauterine progesterone for early stage, low-grade endometrial cancer. Conversely, 65.7% and 45.7% of the most surgeons did not change their management for early stage high-grade and advanced stage endometrial cancers respectively, as they perform surgery. 58% and 67.1% of the surgeons continued to prefer standard surgical treatment for microinvasive and early stage cervical cancers, respectively. Radiotherapy was preferred administered with hypofractionated doses for locally advanced cervical cancer (57.1%). While 67.1% of surgeons operated early stage ovarian cancer patients, 50% administered neoadjuvant chemotherapy (NACT) to all advanced stage ovarian cancers and 50% administered more cycles of NACT in preference to interval debulking surgery. 93.7% of the surgeons responded that treatment should not be delayed beyond eight weeks. Most Turkish gynecologic oncologists modified their management of gynecologic cancers due to the COVID-19 pandemic. While chemotherapy was preferred for ovarian cancer, postponement of the surgery, with or without non-surgical options, was considered for early stage, low-grade endometrial cancer. Treatment of gynecologic cancers should be decided on a case by case basis, taking into account local COVID-19 infection rates and availability of health facilities. Prognosis is also an important consideration if delay is contemplated. Standard treatment and normal time-frames should be used if possible. If not, a postponement for a maximum of eight weeks or referral to another center were acceptable alternatives.
Identifiants
pubmed: 33274616
doi: 10.4274/jtgga.galenos.2020.2020.0071
pmc: PMC7726458
doi:
Types de publication
Journal Article
Langues
eng
Pagination
265-271Références
Cochrane Database Syst Rev. 2019 Oct 31;2019(10):
pubmed: 31684686
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Hum Reprod. 2007 Jul;22(7):1953-8
pubmed: 17449880
J Med Virol. 1991 Jan;33(1):47-50
pubmed: 1901908
Fertil Steril. 2009 Dec;92(6):2122-4
pubmed: 19591991
Facts Views Vis Obgyn. 2020 Apr 1;12(1):3-7
pubmed: 32259155
Mymensingh Med J. 2011 Jul;20(3):507-12
pubmed: 21804521
Int J Gynecol Cancer. 2020 May;30(5):561-563
pubmed: 32221023
J Gynecol Obstet Hum Reprod. 2020 Jun;49(6):101729
pubmed: 32247066
J Minim Invasive Gynecol. 2020 May - Jun;27(4):789-791
pubmed: 32247882
Gynecol Oncol. 2010 Oct;119(1):22-5
pubmed: 20591472
Menopause. 2020 Jul;27(7):771-775
pubmed: 32217887
ESMO Open. 2020 Mar;5(2):
pubmed: 32229501
Int J Gynaecol Obstet. 2020 Jun;149(3):382-383
pubmed: 32275775